Shares of Danish drug maker Novo Nordisk sank about 5-6 % on Friday after U.S. President Donald Trump promised major price cuts for popular weight-loss treatments. The drop reflects investor fears that revenue from drugs like Ozempic and Wegovy might shrink.
Trump, speaking at a White House event on drug costs and fertility treatments, singled out Ozempic, a diabetes drug often used off-label for weight loss. He suggested the drug’s U.S. list price — often over $1,000 per month — could fall to around $150. However, regulators noted that no deal is yet finalised.
Novo Nordisk acknowledged it’s in talks with the U.S. government, but did not provide details. Rival Eli Lilly also saw its stock slip as the broader GLP-1 weight-loss drug market came under pressure.
Analysts said the share decline was driven by headline risk rather than immediate fundamental change. Many insurers already charge much less than $500 a month for the drugs, but the public comments increase uncertainty.
For now, regulators and drugmakers are watching closely. If U.S. pricing rules tighten, the sector could face a shift in margin structure—and that worries investors.
